Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups
about
Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without ImmunotherapyObinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractorinessRole of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: a reviewDanazol induces apoptosis and cytotoxicity of leukemic cells alone and in combination with purine nucleoside analogs in chronic lymphocytic leukemia.Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlationsReal-world clinical experience in the Connect® chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres.miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.Gender and ethnic differences in incidence and survival of lymphoid neoplasm subtypes in an Asian population: Secular trends of a population-based cancer registry from 1998 to 2012.Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model.Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations.Assessment of micro RNAs expression in leukemic cells as prognostic markers in chronic lymphocytic leukemia: micro RNAs can predict survival in a course of the disease.Biological significance and prognostic/predictive impact of complex karyotype in chronic lymphocytic leukemiaTowards the Application of Atorvastatin to Intensify Proapoptotic Potential of Conventional Antileukemic AgentsIn Vitro
P2860
Q28077136-1D14AD2A-BD8D-4CCB-9093-A39AD49850A0Q33416524-11CE417F-1A75-4F1D-B48D-BC9087E56A46Q33424543-9F36CF0D-DD02-4A47-96C6-41357C88CA91Q33709543-191283A3-0C2E-4DA2-AF93-D60717379B6DQ34348572-A8155FFF-EC70-4D9E-9D3D-B82A762B0D36Q36547670-BEEF34BA-C434-443D-9E01-CD3439EFF443Q37260520-AF042D0C-0677-41FD-91A2-19E1A9B0664EQ37462177-C891A471-A62B-438F-9B1F-D6F2D20D698FQ38862227-6F722BB6-CB8D-4774-A62C-679A63528AE5Q41681723-0C497C13-234C-4282-8D52-32F29FDDCF6DQ47571295-13EFE68D-5E9F-493B-8AA5-044052C95882Q50562319-D37FC7FD-959A-4344-9ACF-357075AE9084Q55182677-E0960542-607A-4EA1-8FDD-505CBB4A3307Q57821050-53E46C07-7414-4041-8278-9AAE09CF8402Q59111383-043F42E9-3C14-453A-9FFC-CFB55D1458D0
P2860
Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Modern treatment in chronic ly ...... fficacy in high-risk subgroups
@ast
Modern treatment in chronic ly ...... fficacy in high-risk subgroups
@en
type
label
Modern treatment in chronic ly ...... fficacy in high-risk subgroups
@ast
Modern treatment in chronic ly ...... fficacy in high-risk subgroups
@en
prefLabel
Modern treatment in chronic ly ...... fficacy in high-risk subgroups
@ast
Modern treatment in chronic ly ...... fficacy in high-risk subgroups
@en
P2093
P2860
P50
P356
P1433
P1476
Modern treatment in chronic ly ...... fficacy in high-risk subgroups
@en
P2093
Antonio Cuneo
Elena Saccenti
Giulia Daghia
Maria Ciccone
Olga Sofritti
P2860
P304
P356
10.1002/CAM4.226
P407
P577
2014-03-19T00:00:00Z